Cargando…
Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid
PURPOSE: Metagenomic next-generation sequencing (mNGS) has been widely used to diagnose infectious diseases. However, there are few studies on its diagnostic performance in the central nervous system (CNS) cryptococcosis. This study examined the diagnostic efficacy of mNGS in identifying Cryptococcu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505399/ https://www.ncbi.nlm.nih.gov/pubmed/37724093 http://dx.doi.org/10.2147/IDR.S425463 |
_version_ | 1785106912429211648 |
---|---|
author | Zhang, Xuan Lin, Yaqing Chen, Huixin Hu, Jianhua Zhao, Hong Yang, Meifang Han, Dongsheng |
author_facet | Zhang, Xuan Lin, Yaqing Chen, Huixin Hu, Jianhua Zhao, Hong Yang, Meifang Han, Dongsheng |
author_sort | Zhang, Xuan |
collection | PubMed |
description | PURPOSE: Metagenomic next-generation sequencing (mNGS) has been widely used to diagnose infectious diseases. However, there are few studies on its diagnostic performance in the central nervous system (CNS) cryptococcosis. This study examined the diagnostic efficacy of mNGS in identifying Cryptococcus spp. in cerebrospinal fluid (CSF) samples. PATIENTS AND METHODS: From March 2021 to March 2023, 290 patients with suspected CNS infection were recruited from the First Affiliated Hospital, School of Medicine, Zhejiang University, and 74 patients were ultimately included in the study. Lastly, 22 patients with CNS cryptococcosis were included. Of these patients, 25 CSF samples were enrolled. The diagnostic performance of conventional assays [including India ink, cryptococcal antigen (CrAg) testing, and culture] and mNGS was evaluated for CNS cryptococcosis. RESULTS: In the 25 samples collected, the coincidence rates of mNGS with India ink, CrAg, and culture were 64.0% (16/25), 80.0% (20/25), and 80.0% (20/25), respectively. Without antifungal drug exposure, the coincidence rates were increased to 66.7% (10/15), 100.0% (15/15), and 93.3% (14/15), respectively. The coincidence rates after antifungal therapy were all decreased to 60.0% (6/10), 50.0% (5/10), and 60.0% (6/10), respectively. Moreover, in the 25 samples, the sensitivity of mNGS reached 80.0%, and of India ink, CrAg testing, and culture were 68.0, 100.0, and 60.0%, respectively. The mNGS showed an excellent positive rate (100.0%) in the 15 samples collected without antifungal drug exposure, which was significantly higher than the antifungal drug-exposed group (n = 10) (50.0%) (P = 0.005). The reads of Cryptococcus spp. before antifungal therapy were significantly higher than after it (median, 25,915 vs 2, P = 0.008). CONCLUSION: mNGS is an effective tool for diagnosing CNS cryptococcosis using CSF; however, its sensitivity decreases considerably in patients who have been effectively treated with antifungal drugs. |
format | Online Article Text |
id | pubmed-10505399 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105053992023-09-18 Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid Zhang, Xuan Lin, Yaqing Chen, Huixin Hu, Jianhua Zhao, Hong Yang, Meifang Han, Dongsheng Infect Drug Resist Original Research PURPOSE: Metagenomic next-generation sequencing (mNGS) has been widely used to diagnose infectious diseases. However, there are few studies on its diagnostic performance in the central nervous system (CNS) cryptococcosis. This study examined the diagnostic efficacy of mNGS in identifying Cryptococcus spp. in cerebrospinal fluid (CSF) samples. PATIENTS AND METHODS: From March 2021 to March 2023, 290 patients with suspected CNS infection were recruited from the First Affiliated Hospital, School of Medicine, Zhejiang University, and 74 patients were ultimately included in the study. Lastly, 22 patients with CNS cryptococcosis were included. Of these patients, 25 CSF samples were enrolled. The diagnostic performance of conventional assays [including India ink, cryptococcal antigen (CrAg) testing, and culture] and mNGS was evaluated for CNS cryptococcosis. RESULTS: In the 25 samples collected, the coincidence rates of mNGS with India ink, CrAg, and culture were 64.0% (16/25), 80.0% (20/25), and 80.0% (20/25), respectively. Without antifungal drug exposure, the coincidence rates were increased to 66.7% (10/15), 100.0% (15/15), and 93.3% (14/15), respectively. The coincidence rates after antifungal therapy were all decreased to 60.0% (6/10), 50.0% (5/10), and 60.0% (6/10), respectively. Moreover, in the 25 samples, the sensitivity of mNGS reached 80.0%, and of India ink, CrAg testing, and culture were 68.0, 100.0, and 60.0%, respectively. The mNGS showed an excellent positive rate (100.0%) in the 15 samples collected without antifungal drug exposure, which was significantly higher than the antifungal drug-exposed group (n = 10) (50.0%) (P = 0.005). The reads of Cryptococcus spp. before antifungal therapy were significantly higher than after it (median, 25,915 vs 2, P = 0.008). CONCLUSION: mNGS is an effective tool for diagnosing CNS cryptococcosis using CSF; however, its sensitivity decreases considerably in patients who have been effectively treated with antifungal drugs. Dove 2023-09-13 /pmc/articles/PMC10505399/ /pubmed/37724093 http://dx.doi.org/10.2147/IDR.S425463 Text en © 2023 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Zhang, Xuan Lin, Yaqing Chen, Huixin Hu, Jianhua Zhao, Hong Yang, Meifang Han, Dongsheng Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid |
title | Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid |
title_full | Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid |
title_fullStr | Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid |
title_full_unstemmed | Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid |
title_short | Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid |
title_sort | diagnostic performance of metagenomic next-generation sequencing in central nervous system cryptococcosis using cerebrospinal fluid |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505399/ https://www.ncbi.nlm.nih.gov/pubmed/37724093 http://dx.doi.org/10.2147/IDR.S425463 |
work_keys_str_mv | AT zhangxuan diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid AT linyaqing diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid AT chenhuixin diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid AT hujianhua diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid AT zhaohong diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid AT yangmeifang diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid AT handongsheng diagnosticperformanceofmetagenomicnextgenerationsequencingincentralnervoussystemcryptococcosisusingcerebrospinalfluid |